Gunilla Ekstrom - Karolinska Development Insider

KDEV -- Sweden Stock  

SEK 9.28  0.42  4.33%

  President
Dr. Gunilla Ekstrom was Vice President Operations at Karolinska Development AB since June 2012. Gunilla Ekstrom has over 20 years of experience from senior positions in the pharmaceutical industry including as Senior Vice President at Orexo AB and Global Product Director at AstraZeneca RD. She is also Board member of Athera Biotechnologies AB Biosergen AS Inhalation Sciences Sweden AB Lipidor AB NovaSAID AB Pharmanest AB and CEO of Biosergen AS. She holds Doctorate of Medicine and Doctorate in Philosophy degrees and is Associate Professor at Karolinska Institutet.
Age: 54  President Since 2012  Ph.D    
46 8 52 48 60 70  http://www.karolinskadevelopment.com

Management Efficiency

The company has return on total asset (ROA) of (4.09) % which means that it has lost $4.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 119.32 % meaning that it generated $119.32 on every $100 dollars invested by stockholders.
The company has accumulated 391.46 M in total debt with debt to equity ratio (D/E) of 158.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 16.14 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Karolinska Development AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB was founded in 2003 and is headquartered in Stockholm, Sweden. Karolinska Development operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange. It employs 7 people.Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Tomtebodav?gen 23 A and employs 7 people.

Karolinska Development AB Leadership Team

Hans Wigzell, Independent Chairman of the Board
Elisabet Gimbringer, Controller
Carl Sundberg, Director
Magnus Persson, Director
Jim Heusden, CEO
Maria Ferm, Executive Assistant
HansOlov Olsson, Director
Theresa Tse, Director
Viktor Drvota, Chief Investment Officer
Eva Montgomerie, Head of Accounting
Michael Owens, Controller
Yan Cheng, President Asia
Ulf Richenberg, General Counsel
Niclas Adler, Director
Tse Ping, Director
Christian Tange, CFO
Daniel Bolanowski, Business Analyst
Terje Kalland, Chief Scientific Officer
Vladimir Artamonov, Independent Director
Felicia Rittemar, Analyst
AnnSofie Sternas, Vice President IPR
Anders Harfstrand, Director
Bo Hansen, Chairman of the Board
Fredrik Jarrsten, CFO
Khalid Islam, Director
Gunilla Ekstrom, Vice President - Operations
Henrijette Richter, Director

Stock Performance Indicators

Current Sentiment - KDEV

Karolinska Development AB Investor Sentiment
Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Karolinska Development AB. What is your trading attitude regarding investing in Karolinska Development AB? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">